By physician referral or invitation only

AMGEN Phase 2 ANCA-associated vasculitis

The rationale of this phase 3 study is to explore whether avacopan combined with a rituximab or cyclophosphamide-containing regimen is safe and effective in inducing and maintaining remission in pediatric subjects with active ANCA-associated vasculitis (AAV).

Age & Gender

6 years ~ 17 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Eveline Wu
Pediatrics - Children's Research Institute

Study Type

Clinical or Medical
Interventional

Study Topics

Heart and Circulation
Immune System/Infections
Rare Diseases

IRB Number

24-0683

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.